News Category
Medical experts are urging small cell lung cancer patients to ask about clinical trials at their first appointment, as emerging treatments offer new h...
Oncotelic Therapeutics announced that its Sapu003 Phase 1b trial passed an initial safety review with no dose-limiting toxicities, and the company pla...
NanoViricides announced that the Democratic Republic of Congo's Pillar Committee has approved its proposal for a Phase II clinical trial of NV-387 Ora...
Mark L. Fox's 'The Memory Room' explores 40 Hz gamma stimulation and a wearable device that showed cognitive improvements in a Phase 1 study, offering...
Tonix Pharmaceuticals announced its participation in BTIG Infectious Disease Day 2026, highlighting its immunology pipeline including Lyme disease pro...
The U.S. National ALS Registry urges individuals with ALS to enroll and complete risk factor surveys to help researchers understand causes and improve...
SureNano Science Ltd. initiates GLP toxicology and pharmacology programs for its lead obesity drug GEP-44, a necessary step before IND application and...
Optimi Health Corp. has shipped naturally derived psilocybin to the United Kingdom for a planned Phase 2 clinical trial, marking a key milestone in in...
Quantum BioPharma reports positive Phase 1 trial results for its LUCID-MS therapy targeting myelin repair in multiple sclerosis, addressing a critical...
Ventiv Scientific's first-in-human clinical cases using its V-PULSE Mechanical Thrombectomy System show effective clot removal with real-time aspirati...
A new review in the World Journal of Pediatrics shows that immediate skin-to-skin care, or kangaroo mother care, started within 24 hours of birth sign...
Regentis Biomaterials announced plans to start surgeon training in Europe for its CE Mark-approved knee cartilage treatment GelrinC, advancing its com...
A clinical trial called ROADS, presented at the 2026 ASCO meeting by MD Anderson Cancer Center, showed that placing radioactive collagen tiles in the ...
Quantum BioPharma announced the completion of Phase 1 clinical studies for LUCID-MS, a therapy targeting myelin repair in multiple sclerosis, and subm...
TransCode Therapeutics will host its first R&D webcast on June 18, 2026, to discuss its Phase 2a trial of TTX-MC138 in colorectal cancer and broader p...
New research published in JCI Insight suggests that GeoVax's Gedeptin therapy could enhance immune checkpoint inhibitor responses and activate systemi...
Lifordi's novel subcutaneous glucocorticoid antibody-drug conjugate shows safety and anti-inflammatory activity without cortisol suppression in health...
New findings from HighTide Therapeutics show that HTD1801 improves renal function and protects podocytes, potentially offering a disease-modifying the...
Quantum BioPharma is advancing a novel multiple sclerosis therapy through its subsidiary Lucid Psycheceuticals and expanding into the alcohol health m...
Regentis Biomaterials' GelrinC platform targets a large orthopedic market lacking an approved off-the-shelf regenerative cartilage repair option, with...
NeuroThera Labs Inc. has completed its acquisition of a 54.01% stake in CliniQuantum Ltd., a quantum simulation company focused on improving clinical ...
Dr. Robert Whitfield's clinical safety research on fat transfer breast augmentation, paired with a new explant option for Breast Implant Illness patie...
Oncotelic Therapeutics announces the expansion of its Phase 1b clinical program for Sapu003 and the appointment of Global Clinical Trials to lead inte...
TransCode Therapeutics announced positive Phase 1a trial results for its microRNA-10b inhibitor TTX-MC138, showing safety and durable disease stabiliz...
Onco-Innovations Limited announced successful kilogram-scale production of the B4 precursor for its lead PNKP inhibitor ONC010, advancing toward clini...
The American Heart Association has selected 15 centers for a new research network aimed at transforming heart transplant care through improved data in...
Viromed Medical AG announces successful completion of a multi-year study on cold atmospheric plasma application in the lung, confirming potential as a...
Quantum BioPharma's co-founder discusses the company's promising MS drug candidate Lucid-MS and commercial alcohol metabolism product unbuzzd™, highli...
Regentis Biomaterials is progressing its cell-free hydrogel implant GelrinC through pivotal trials, targeting a $3 billion U.S. market for knee cartil...
Regentis Biomaterials advances its GelrinC platform through pivotal U.S. Phase III trial, aiming to disrupt the $3 billion knee cartilage repair marke...
Lantern Pharma's LP-300 combination therapy shows improved progression-free survival in L858R-mutant non-small cell lung cancer patients, with FDA-cle...
Quantum BioPharma's co-founder discusses the potential of Lucid-MS for multiple sclerosis and the commercial success of unbuzzd, with an upcoming Phas...
Quantum BioPharma's lead drug candidate Lucid-MS targets mobility loss in multiple sclerosis by addressing nerve damage, while its commercial product ...
Regentis Biomaterials advances GelrinC, a cell-free hydrogel implant for knee cartilage repair, toward European commercialization and U.S. Phase III t...
Regentis Biomaterials' cell-free hydrogel implant GelrinC aims to simplify knee cartilage repair, targeting a $3 billion U.S. market with promising cl...
New data presented by Tonix Pharmaceuticals reveals that despite guidelines discouraging opioid use, nearly 40% of fibromyalgia patients are prescribe...
Regentis Biomaterials' GelrinC, a potential first-in-class off-the-shelf solution for knee cartilage repair, shows superior pain relief in clinical tr...
Regentis Biomaterials is progressing its off-the-shelf hydrogel implant GelrinC through U.S. FDA trials to fill a gap in knee cartilage repair, target...
Oncotelic Therapeutics and Sapu Nano will present their Deciparticle nanomedicine platform at the BIO International Convention 2026, showcasing ultra-...
Jupiter Neurosciences closed a $2 million registered direct offering to fund its clinical programs for CNS disorders and neuroinflammation.
Quantum BioPharma Ltd. is progressing a clinical-stage multiple sclerosis program targeting demyelination, with Phase 1 safety studies completed and a...
Tonix Pharmaceuticals announced publication of positive Phase 1 data for its anti-CD40L monoclonal antibody TNX-1500, showing favorable safety and tol...
TransCode Therapeutics has launched a Phase 2a clinical trial of its lead candidate TTX-MC138 in colorectal cancer patients with minimal residual dise...
Regentis Biomaterials is advancing GelrinC, a cell-free hydrogel implant for knee cartilage repair, as clinical trials progress and a new manufacturin...
Tonix Pharmaceuticals presented real-world claims analysis at ISPOR 2026 showing that over 93% of fibromyalgia patients have comorbidities and incur s...
Regentis Biomaterials is advancing its off-the-shelf GelrinC hydrogel implant for knee cartilage repair, with a pivotal U.S. FDA trial over 50% enroll...
Telomir Pharmaceuticals announced peer-reviewed preclinical data showing Telomir-Zn improved survival and reduced copper burden in Wilson’s disease mo...
Annovis Bio (NYSE: ANVS) has announced a proposed public offering of common stock and warrants to fund the Phase 3 clinical development of buntanetap ...
